Увійти

Готові списки джерел за темами / Major cardiovascular events / Статті в журналах

Статті в журналах з теми "Major cardiovascular events"

Щоб переглянути інші типи публікацій з цієї теми, перейдіть за посиланням: Major cardiovascular events.

Автор: Grafiati

Опубліковано: 28 вересня 2022

Оновлено: 28 січня 2023

Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями

Оберіть тип джерела:

Ознайомтеся з топ-50 статей у журналах для дослідження на тему "Major cardiovascular events".

Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.

Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.

Переглядайте статті в журналах для різних дисциплін та оформлюйте правильно вашу бібліографію.

1

Radensky, Paul W., Elise Berliner, Jennifer W. Archer, and Susan F. Dournaux. "Inpatient Costs of Major Cardiovascular Events." American Journal of Cardiovascular Drugs 1, no. 3 (2001): 205–17. http://dx.doi.org/10.2165/00129784-200101030-00006.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

2

Duceppe, Emmanuelle, John Harlock, Stephane Elkouri, Luc Dubois, Joel Parlow, Rikesh Parekh, Vikas Tandon, et al. "MAJOR CARDIOVASCULAR EVENTS FOLLOWING ENDOVASCULAR ANEURYSM REPAIR." Journal of the American College of Cardiology 77, no. 18 (May 2021): 1811. http://dx.doi.org/10.1016/s0735-1097(21)03167-3.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

3

Szekeres, Norbert A., Zsuzsánna Jeremiás, Árpád Olivér Vida, Orsolya Mártha, and Daniel Porav-Hodade. "Can Erectile Dysfunction Predict Major Cardiovascular Events?" Journal of Interdisciplinary Medicine 1, no. 1 (June 1, 2016): 18–22. http://dx.doi.org/10.1515/jim-2016-0005.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

AbstractIt is estimated that erectile dysfunction (ED) affects more than 150 million people worldwide and this number is expected to double by the year 2025. Vascular component represents the most important etiological cause of erectile dysfunction. ED shares almost all risk factors, such as hypertension, diabetes mellitus, hyperlipidaemia and smoking, with arteriosclerosis. Moderate to severe ED is associated with a considerably increased risk for coronary heart disease (CHD). This review was conducted in May 2016, when the PubMed database was searched using the combination of the terms “erectile dysfunction” and “cardiovascular diseases”, “coronary artery diseases” and “risk factors”. In this review, we analyzed the published literature, regarding the predictive role of ED in CVD and the association of ED risk factors with CVD risk factors, aiming to draw particular attention on the role of sexual inquiry of all men to prevent or decrease major cardiovascular events. In conclusion, the early detection of ED can prevent major cardiovascular events with early management of cardiovascular risk and permits to include patients in a risk stratification group. Erectile function should be evaluated using questionnaires in all male patients to prevent and decrease the rates of major cardiovascular events.

4

Khan, Safinaz, Rubaya Rashid, A. H. M. Ataullah, and Md Moshiur Rahman. "Hyperhomocysteinemia affecting cardiovascular and other major organ events." IJS Short Reports 7, no. 3 (July 2022): e40-e40. http://dx.doi.org/10.1097/sr9.0000000000000040.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

5

Szmulewicz, Alejandro G., Federico Angriman, Felipe E. Pedroso, Carolina Vazquez, and Diego J. Martino. "Long-Term Antipsychotic Use and Major Cardiovascular Events." Journal of Clinical Psychiatry 78, no. 8 (October 25, 2017): e905-e912. http://dx.doi.org/10.4088/jcp.16m10976.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

6

Ray, Kausik K., Henry N. Ginsberg, Michael H. Davidson, Robert Pordy, Laurence Bessac, Pascal Minini, Robert H. Eckel, and Christopher P. Cannon. "Reductions in Atherogenic Lipids and Major Cardiovascular Events." Circulation 134, no. 24 (December 13, 2016): 1931–43. http://dx.doi.org/10.1161/circulationaha.116.024604.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

7

Eaton MD, Charles B. "Rosuvastatin reduced major cardiovascular events in patients at intermediate cardiovascular risk." Annals of Internal Medicine 165, no. 2 (July 19, 2016): JC6. http://dx.doi.org/10.7326/acpjc-2016-165-2-006.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

8

Peluso, Rosario, Francesco Caso, Marco Tasso, Pasquale Ambrosino, Matteo Nicola, Dario Di Minno, Roberta Lupoli, et al. "Cardiovascular Risk Markers and Major Adverse Cardiovascular Events in Psoriatic Arthritis Patients." Reviews on Recent Clinical Trials 13, no. 3 (August 1, 2018): 199–209. http://dx.doi.org/10.2174/1574887113666180314105511.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

9

Aksu, Uğur, Oktay Gulcu, Emrah Aksakal, and Kamuran Kalkan. "Endocan and Major Adverse Cardiovascular Events: Understanding Regression Methods." Angiology 70, no. 10 (February 10, 2019): 982. http://dx.doi.org/10.1177/0003319719828911.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

10

Gu, Haotian, Majid Akhtar, Amit Shah, Anjalika Mallick, Marlies Ostermann, and John Chambers. "Echocardiography Predicts Major Adverse Cardiovascular Events after Renal Transplantation." Nephron Clinical Practice 126, no. 1 (2014): 75–80. http://dx.doi.org/10.1159/000358885.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

11

Udell, Jacob A., Hong Lu, and Donald A. Redelmeier. "FAILED FERTILITY THERAPY AND SUBSEQUENT MAJOR ADVERSE CARDIOVASCULAR EVENTS." Journal of the American College of Cardiology 63, no. 12 (April 2014): A2163. http://dx.doi.org/10.1016/s0735-1097(14)62166-5.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

12

Cordero, Alberto, Carlos G. Santos-Gallego, Lorenzo Fácila, Moisés Rodríguez-Mañero, Vicente Bertomeu-González, Jose M. Castellano, José Seijas-Amigo, et al. "Estimation of the major cardiovascular events prevention with Inclisiran." Atherosclerosis 313 (November 2020): 76–80. http://dx.doi.org/10.1016/j.atherosclerosis.2020.09.021.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

13

Lebwohl, Mark. "Interleukin 12/23 Agents and Major Adverse Cardiovascular Events." Archives of Dermatology 148, no. 11 (November 1, 2012): 1329. http://dx.doi.org/10.1001/2013.jamadermatol.88.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

14

Furberg, Curt D., Robert P. Byington, John R. Crouse, and Mark A. Espeland. "Pravastatin, lipids, and major coronary events." American Journal of Cardiology 73, no. 15 (June 1994): 1133–34. http://dx.doi.org/10.1016/0002-9149(94)90297-6.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

15

Goodman, Shaun G., Daniel M. Wojdyla, Jonathan P. Piccini, Harvey D. White, John F. Paolini, Christopher C. Nessel, Scott D. Berkowitz, et al. "Factors Associated With Major Bleeding Events." Journal of the American College of Cardiology 63, no. 9 (March 2014): 891–900. http://dx.doi.org/10.1016/j.jacc.2013.11.013.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

16

Michel, Adrian, Ramy Mando, Muhammad Abdul-Aziz Waheed, Alexandra Halalau, and Patrick Karabon. "PREDIABETES ASSOCIATED WITH AN INCREASE IN MAJOR ADVERSE CARDIOVASCULAR EVENTS." Journal of the American College of Cardiology 77, no. 18 (May 2021): 14. http://dx.doi.org/10.1016/s0735-1097(21)01357-7.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

17

Sloan, Michael A. "Telmisartan did not prevent recurrent stroke or major cardiovascular events." Annals of Internal Medicine 150, no. 4 (February 17, 2009): JC2. http://dx.doi.org/10.7326/0003-4819-150-4-200902170-02009.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

18

Bacci, Simonetta, Stefano Rizza, Sabrina Prudente, Belinda Spoto, Christine Powers, Antonio Facciorusso, Antonio Pacilli, et al. "TheENPP1Q121 Variant Predicts Major Cardiovascular Events in High-Risk Individuals." Diabetes 60, no. 3 (January 31, 2011): 1000–1007. http://dx.doi.org/10.2337/db10-1300.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

19

Sun, Jian-zhong, Hai-long Dong, Li-nong Yao, and Hong Liu. "Preventing Perioperative Major Adverse Cardiovascular Events in Patients with Diabetes." Journal of Anesthesia and Perioperative Medicine 2, no. 2 (March 2015): 96–106. http://dx.doi.org/10.24015/japm.2015.0014.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

20

Lee‐Lane, Elinor, Fatemeh Torabi, Arron Lacey, Beata Fonferko‐Shadrach, Daniel Harris, Ashley Akbari, Ronan A. Lyons, et al. "Epilepsy, antiepileptic drugs, and the risk of major cardiovascular events." Epilepsia 62, no. 7 (May 27, 2021): 1604–16. http://dx.doi.org/10.1111/epi.16930.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

21

Mando, Ramy, Muhammad Waheed, Adrian Michel, Patrick Karabon, and Alexandra Halalau. "Prediabetes as a risk factor for major adverse cardiovascular events." Annals of Medicine 53, no. 1 (January 1, 2021): 2090–98. http://dx.doi.org/10.1080/07853890.2021.2000633.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

22

Tzellos, Thrasivoulos, Athanassios Kyrgidis, Anastasia Trigoni, and Christos C. Zouboulis. "Association of ustekinumab and briakinumab with major adverse cardiovascular events." Dermato-Endocrinology 4, no. 3 (July 2012): 320–23. http://dx.doi.org/10.4161/derm.23100.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

23

Capuano, Vincenzo, Federica Marchese, Rocco Capuano, Sergio Torre, Anna G. Iannone, Eduardo Capuano, Norman Lamaida, Matteo Sonderegger, and Ernesto Capuano. "Hyperuricemia as an independent risk factor for major cardiovascular events." Journal of Cardiovascular Medicine 18, no. 3 (March 2017): 159–64. http://dx.doi.org/10.2459/jcm.0000000000000347.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

24

Mortazavi, Bobak J., Nihar Desai, Jing Zhang, Andreas Coppi, Fred Warner, Harlan M. Krumholz, and Sahand Negahban. "Prediction of Adverse Events in Patients Undergoing Major Cardiovascular Procedures." IEEE Journal of Biomedical and Health Informatics 21, no. 6 (November 2017): 1719–29. http://dx.doi.org/10.1109/jbhi.2017.2675340.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

25

Sobey, Christopher G., Courtney P. Judkins, Vijaya Sundararajan, Thanh G. Phan, Grant R. Drummond, and Velandai K. Srikanth. "Risk of Major Cardiovascular Events in People with Down Syndrome." PLOS ONE 10, no. 9 (September 30, 2015): e0137093. http://dx.doi.org/10.1371/journal.pone.0137093.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

26

Barash, P., and S. Akhtar. "Coronary stents: factors contributing to perioperative major adverse cardiovascular events." British Journal of Anaesthesia 105 (December 2010): i3—i15. http://dx.doi.org/10.1093/bja/aeq318.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

27

Gaist, David, Stine Munk Hald, Luis Alberto García Rodríguez, Anne Clausen, Sören Möller, Jesper Hallas, and Rustam Al-Shahi Salman. "Association of Prior Intracerebral Hemorrhage With Major Adverse Cardiovascular Events." JAMA Network Open 5, no. 10 (October 3, 2022): e2234215. http://dx.doi.org/10.1001/jamanetworkopen.2022.34215.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

ImportancePatients with stroke due to nontraumatic (spontaneous) intracerebral hemorrhage (ICH) often harbor vascular risk factors and comorbidities, but it is unclear which major adverse cardiovascular events (MACEs) occur more frequently among patients with a prior ICH than the general population.ObjectiveTo evaluate the risk of a MACE for patients with a prior ICH compared with the general population.Design, Setting, and ParticipantsThis cohort study identified 8991 patients with a first ICH in the Danish Stroke Registry from January 1, 2005, to June 30, 2018, who were aged 45 years or older and survived more than 30 days after an ICH. Patients in this ICH cohort were matched 1:40 on age, sex, and ICH-onset date with a comparison cohort of 359 185 individuals from the general population without a prior ICH. Both cohorts were followed up for 6 months or more until December 31, 2018, for outcomes using registry data. Data were analyzed from October 1, 2021, to July 19, 2022.ExposuresIntracerebral hemorrhage identified by a nationwide clinical database.Main Outcomes and MeasuresThe main outcomes were ICH, ischemic stroke, myocardial infarction, and a composite of MACEs. For each outcome, a case-control study nested within the cohorts was also performed, adjusting for time-varying exposures and potential confounders. Crude absolute event rates per 100 person-years, adjusted hazard ratios (aHRs) and 95% CIs and, in the nested case-control analyses, crude and adjusted odds ratios and 95% CIs were calculated.ResultsThe ICH cohort (n = 8991; 4814 men [53.5%]; mean [SD] age, 70.7 [11.5] years) had higher event rates than the comparison cohort (n = 359 185; 192 256 men [53.5%]; mean [SD] age, 70.7 [11.5] years) for MACEs (4.16 [95% CI, 3.96-4.37] per 100 person-years vs 1.35 [95% CI, 1.33-1.36] per 100 person-years; aHR, 3.13 [95% CI, 2.97-3.30]), ischemic stroke (1.52 [95% CI, 1.40-1.65] per 100 person-years vs 0.56 [95% CI, 0.55-0.57] per 100 person-years; aHR, 2.64 [95% CI, 2.43-2.88]), and ICH (1.44 [95% CI, 1.32-1.56] per 100 person-years vs 0.06 [95% CI, 0.06-0.07] per 100 person-years; aHR, 23.49 [95% CI, 21.12-26.13]) but not myocardial infarction (0.52 [95% CI, 0.45-0.60] per 100 person-years vs 0.48 [95% CI, 0.47-0.49] per 100 person-years; aHR, 1.12 [95% CI, 0.97-1.29]). Nested case-control analyses returned risk estimates of similar magnitude as the cohort analyses.Conclusions and RelevanceThe findings of this cohort study suggest that Danish patients with a prior ICH had statistically significantly higher rates of MACEs than the general population, indicating a need for attention to optimal secondary prevention with blood pressure lowering and antithrombotic and statin therapies after an ICH in clinical research and practice.

28

Gill, Gauravpal S., Stephen J. Fernandez, Nidhi Malhotra, Mihriye Mete, and Hector M. Garcia-Garcia. "Major acute cardiovascular events in patients with inflammatory bowel disease." Coronary Artery Disease 32, no. 1 (April 16, 2020): 73–77. http://dx.doi.org/10.1097/mca.0000000000000899.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

29

Essouma, Mickael, Jean Joel R. Bigna, and Jean Jacques N. Noubiap. "Household Air Pollution, Intermediate Outcomes, and Major Adverse Cardiovascular Events." Journal of Clinical Hypertension 18, no. 5 (October 22, 2015): 479–80. http://dx.doi.org/10.1111/jch.12719.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

30

Tu, Jack V., Anna Chu, Mohammad R. Rezai, Helen Guo, Laura C. Maclagan, Peter C. Austin, Gillian L. Booth, et al. "Incidence of Major Cardiovascular Events in Immigrants to Ontario, Canada." Circulation 132, no. 16 (October 20, 2015): 1549–59. http://dx.doi.org/10.1161/circulationaha.115.015345.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

31

Boschiero, L., F. Fior, and F. Nacchia. "Bimodal Distribution of Major Cardiovascular Events in Kidney Allograft Recipients." Transplantation Proceedings 41, no. 4 (May 2009): 1183–86. http://dx.doi.org/10.1016/j.transproceed.2009.02.047.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

32

Mehta FAHA, Nehal N., Rebecca Pinnelas, Parasuram Krishnamoorthy, Yiding Yu, Daniel Shin, Andrea Troxel, and Joel M. Gelfand. "ATTRIBUTABLE RISK ESTIMATE OF SEVERE PSORIASIS ON MAJOR CARDIOVASCULAR EVENTS." Journal of the American College of Cardiology 57, no. 14 (April 2011): E486. http://dx.doi.org/10.1016/s0735-1097(11)60486-5.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

33

Rott, David. "Low-Density Lipoprotein Levels and Risk of Major Cardiovascular Events." JAMA Internal Medicine 176, no. 12 (December 1, 2016): 1876. http://dx.doi.org/10.1001/jamainternmed.2016.6862.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

34

Mehta, Nehal N., YiDing Yu, Rebecca Pinnelas, Parasuram Krishnamoorthy, Daniel B. Shin, Andrea B. Troxel, and Joel M. Gelfand. "Attributable Risk Estimate of Severe Psoriasis on Major Cardiovascular Events." American Journal of Medicine 124, no. 8 (August 2011): 775.e1–775.e6. http://dx.doi.org/10.1016/j.amjmed.2011.03.028.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

35

Davies, Michael J., Franklin Sun, Phillip Banks, Deepak L. Bhatt, and Bertram Pitt. "Major Adverse Cardiovascular Events Across the Sotagliflozin Clinical Development Program." American Heart Journal 254 (December 2022): 243–44. http://dx.doi.org/10.1016/j.ahj.2022.10.033.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

36

Noumegni, Steve Raoul, Romain Didier, Vincent Mansourati, Emmanuelle Le Moigne, Raphael Le Mao, Clément Hoffmann, Claire De Moreuil, et al. "Risk Factors for Major Adverse Cardiovascular Events and Major Adverse Limb Events after Venous Thromboembolism: A Large Prospective Cohort Study." Seminars in Thrombosis and Hemostasis 48, no. 04 (June 2022): 465–80. http://dx.doi.org/10.1055/s-0042-1748152.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

Abstract Background There is an increased risk of arterial events including major adverse cardiovascular events (MACE) and major adverse limb events (MALE) after venous thromboembolism (VTE). However, their risk factors remain little explored. Methods We aimed to determine the risk factors for MACE (acute coronary syndrome/stroke/cardiovascular death) and MALE (limb ischemia/critical limb ischemia/non-traumatic amputation/any limb revascularization) after VTE. Competing risk models (Fine-Gray) were used in a multicenter prospective cohort of 4,940 patients (mean age: 64.6 years and median follow-up: 64 months). Results MACE occurred in 17.3% of participants (2.35% per patient-years) and MALE in 1.7% (0.27% per patient-years). In multivariable analysis, the identified risk factors for MACE were the age of 50 to 65 years (vs. <50 years, hazard ratio [HR]: 2.00, 95% confidence interval [CI]: 1.38–2.91), age >65 years (vs. <50 years, HR 4.85, 95% CI: 3.35–7.02), pulmonary embolism + deep vein thrombosis (DVT) (vs. isolated-DVT, HR: 1.25, 95% CI: 1.02–1.55), unprovoked-VTE (vs. transient risk factor associated-VTE, HR: 1.29, 95% CI: 1.04–1.59), current tobacco use (vs. never, HR: 1.45, 95% CI: 1.07–1.98), hypertension (HR: 1.61, 95% CI: 1.30–1.98), past history of symptomatic atherosclerosis (HR: 1.52, 95% CI: 1.17–1.98), heart failure (HR: 1.71, 95% CI: 1.21–2.42), atrial fibrillation (HR: 1.55, 95% CI: 1.15–2.08), and vena cava filter insertion (HR: 1.46, 95% CI: 1.03–2.08). The identified risk factors for MALE were the age of 50–65 years (vs. <50 years, HR: 3.49, 95% CI: 1.26–9.65) and atrial fibrillation (HR: 2.37, 95% CI: 1.15–4.89). Conclusions Risk factors for MACE and MALE after VTE included some traditional cardiovascular risk factors, patient's comorbidities, and some characteristics of VTE.

37

Koffer, Rachel, Rebecca Thurston, and Karen Matthews. "LIFE EVENTS AND CARDIOVASCULAR DISEASE EVENTS: THE STUDY OF WOMEN'S HEALTH ACROSS THE NATION." Innovation in Aging 6, Supplement_1 (November 1, 2022): 173. http://dx.doi.org/10.1093/geroni/igac059.689.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

Abstract Cardiovascular disease (CVD) is the number one cause of death for women, and major life events across midlife may contribute to CVD risk. The present study aimed to test whether greater exposure to major life events across nearly two decades of longitudinal follow-up would be associated with higher risk of clinical cardiovascular disease events. 3,222 middle-aged women from the multi-ethnic Study of Women’s Health Across the Nation reported and provided up to 15 years of major life events, non-fatal incident CVD events, traditional biobehavioral and sociodemographic factors, and death certificates. Cox proportional hazards models were used to test the association between average annual life events and incident fatal and nonfatal CVD events. Each additional major life event was associated with a 1.16-fold (95% CI: 1.08-1.23) increase in CVD events. CVD risk will be discussed considering evidence of racial/ethnic disparities in exposure to major life events.

38

Wang, Tiange, Jieli Lu, Qing Su, Yuhong Chen, Yufang Bi, Yiming Mu, Lulu Chen, et al. "Ideal Cardiovascular Health Metrics and Major Cardiovascular Events in Patients With Prediabetes and Diabetes." JAMA Cardiology 4, no. 9 (September 1, 2019): 874. http://dx.doi.org/10.1001/jamacardio.2019.2499.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

39

Bush, R. G., M. Derrick, and D. Manjoney. "Major neurological events following foam sclerotherapy." Phlebology: The Journal of Venous Disease 23, no. 4 (August 2008): 189–92. http://dx.doi.org/10.1258/phleb.2007.007073.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

Aim This report describes two complications of severe neurologic alterations (TIA, CVA) after foamed sclerotherapy injection. Methods Using foam sclerotherapy in accepted concentrations, volume, and in standard ratio of air to sclerosant, two serious neurologic complications occurred. Results In both cases described, unknown atrial communications existed resulting in foam emboli. One case involving the vertebral system resolved without treatment. The other involving the cerebral system was treated with hyperbaric oxygen. Conclusions Foam sclerotherapy can cause serious neurologic phenomenon even though the incidence is rarely described. Immediate treatment with 100% O2 and possible hyperbaric O2 therapy should be considered.

40

Nartsissova, G. P., I. I. Volkova, I. G. Zorina, O. Yu Malakhova, D. S. Prokhorova, N. V. Zholobova, and T. A. Latortseva. "DIAGNOSTIC ULTRASOUND ALGORITHMS FOR ACUTE CARDIOVASCULAR EVENTS." Siberian Medical Journal 33, no. 4 (February 13, 2019): 27–37. http://dx.doi.org/10.29001/2073-8552-2018-33-4-27-37.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

The article describes the principles of ultrasonic diagnosis of acute cardiovascular events including focused echocardiography protocol. Authors present brief diagnostic ultrasound algorithms for some acute cardiovascular events and describe the clinical manifestations and the major echocardiographic signs to help the practical doctor to quickly establish the precise diagnosis in emergencies.

41

Koval, O. A. "NEPTUNO STUDY: polypill Trinomia use decreased risk of major adverse cardiovascular events." Medicine of Ukraine, no. 2(258) (July 13, 2022): 35–39. http://dx.doi.org/10.37987/1997-9894.2022.2(258).264210.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

The article presents an overview of domestic and international research on the feasibility and effectiveness of using a strategy of combining several drugs with fixed doses in one pill - a polypill - in patients with cardiovascular diseases, in particular after an acute coronary syndrome, with the aim of secondary prevention of repeated adverse events . The NEPTUNO study showed that the use of a cardiovascular combination drug containing acetylsalicylic acid, ramipril, atorvastatin (CNIC-Polypill) was associated with a significant reduction in the rate of recurrence of major adverse cardiovascular events, along with a delay in time to event, in in a large sample of real patients with a history of atherosclerotic cardiovascular disease in comparison with three different control groups of active treatment (monocomponent, equipotent and other therapy). In addition, the use of CNIC-Polypill provided better blood pressure and lipid control, as well as longer duration of continuous medication. The results of the NEPTUNO study confirmed the usefulness of this strategy for the secondary prevention of cardiovascular diseases.

42

Fernández-Laso, Valvanera, Cristina Sastre, Jose M. Valdivielso, Angels Betriu, Elvira Fernández, Jesús Egido, Jose L. Martín-Ventura, and Luis M. Blanco-Colio. "Soluble TWEAK and Major Adverse Cardiovascular Events in Patients with CKD." Clinical Journal of the American Society of Nephrology 11, no. 3 (January 4, 2016): 413–22. http://dx.doi.org/10.2215/cjn.07900715.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

43

Stoimenov, B., R. Pancheva, S. Dineva, E. Manov, V. Pencheva, and N. Rune. "Major adverse cardiovascular events in bulgarian patients with chronic coronary syndrome." Nigerian Journal of Clinical Practice 25, no. 5 (2022): 710. http://dx.doi.org/10.4103/njcp.njcp_33_22.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

44

Gami, Apoor S., and Steven A. Smith. "Atorvastatin reduced major cardiovascular disease events in type 2 diabetes mellitus." ACP Journal Club 142, no. 2 (March 1, 2005): 29. http://dx.doi.org/10.7326/acpjc-2005-142-2-029.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

45

Haykal, T. M., Rizki, Lira Firiana, Wibisono Firmanda, Rarsari Soerarso, Nani Hersunarti, and Bambang B. Siswanto. "Diabetic State and Major Cardiovascular Events in young adult hypertensive patients." Journal of Hypertension 33 (June 2015): e32. http://dx.doi.org/10.1097/01.hjh.0000469835.68789.da.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

46

Yeh, Chao‐Bin, Ming‐Che Tsai, Ying‐Hock Teng, Min‐Sho Ku, Jing‐Yang Huang, Bo‐Yuan Wang, Chia‐Ling Tai, Edy Kornelius, and Sai‐Wai Ho. "Association of alprazolam with major cardiovascular events in patients with hypertension." Journal of Evaluation in Clinical Practice 26, no. 3 (August 6, 2019): 983–91. http://dx.doi.org/10.1111/jep.13254.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

47

Stanbrook, M. B. "Review: inhaled anticholinergics increase risk of major cardiovascular events in COPD." Evidence-Based Medicine 14, no. 2 (April 1, 2009): 42–43. http://dx.doi.org/10.1136/ebm.14.2.42.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

48

Delanghe, J. R., M. L. De Buyzere, G. G. Leroux-Roels, and D. L. Clement. "Can Creatine Predict Further Major Cardiovascular Events after Acute Myocardial Infarction?" Annals of Clinical Biochemistry: An international journal of biochemistry and laboratory medicine 28, no. 1 (January 1, 1991): 101–2. http://dx.doi.org/10.1177/000456329102800118.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

49

Sierra, P., S. Sabate, J. C. Ortiz, A. Mases, and D. Hernando. "Is pre-induction hypertension associated with perioperative major adverse cardiovascular events?" European Journal of Anaesthesiology 28 (June 2011): 48–49. http://dx.doi.org/10.1097/00003643-201106001-00150.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

50

Korsnes, J. S. "Evaluation Of Hospital Resource Utilization Associated With Major Adverse Cardiovascular Events." Value in Health 17, no. 3 (May 2014): A111—A112. http://dx.doi.org/10.1016/j.jval.2014.03.650.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.